Sutro Biopharma (STRO) Enterprise Value (2016 - 2025)
Sutro Biopharma (STRO) has disclosed Enterprise Value for 10 consecutive years, with -$141.4 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 55.37% to -$141.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$141.4 million through Dec 2025, up 55.37% year-over-year, with the annual reading at -$141.4 million for FY2025, 55.37% up from the prior year.
- Enterprise Value hit -$141.4 million in Q4 2025 for Sutro Biopharma, up from -$167.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$66.6 million in Q1 2022 to a low of -$358.3 million in Q2 2023.
- Historically, Enterprise Value has averaged -$192.9 million across 5 years, with a median of -$182.3 million in 2021.
- Biggest five-year swings in Enterprise Value: soared 69.74% in 2022 and later tumbled 277.32% in 2023.
- Year by year, Enterprise Value stood at -$160.8 million in 2021, then plummeted by 88.08% to -$302.3 million in 2022, then surged by 63.22% to -$111.2 million in 2023, then plummeted by 184.96% to -$316.9 million in 2024, then surged by 55.37% to -$141.4 million in 2025.
- Business Quant data shows Enterprise Value for STRO at -$141.4 million in Q4 2025, -$167.6 million in Q3 2025, and -$205.1 million in Q2 2025.